FGFR2 and cholangiocarcinoma: The clinical benefits and manageable safety profile of pemigatinib in patients with cholangiocarcinoma carrying FGFR2 fusions or rearrangements were demonstrated in the FIGHT‐202 study, which was a single‐arm, phase II study that enrolled patients with FGFR2 fusions or rearrangements (n = 107), other FGF/FGFR alterations (n = 20), and no FGF/FGFR alterations (n = 18) from multiple countries, not including mainland China.26